Inhibition of ebola and marburg virus entry by G protein-coupled receptor antagonists

Journal of Virology

Volumn 89, Issue 19, 2015, Pages 9932-9938

  Cheng, Han ^a   Lear Rooney, Calli M ^b   Johansen, Lisa ^c   Varhegyi, Elizabeth ^a   Chen, Zheng W ^a   Olinger, Gene G ^b,d   Rong, Lijun ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

^b UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^c Molecular Biotechnology Center   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR; ANTIVIRUS AGENT; BENZATROPINE MESILATE; CYPROHEPTADINE; DILAZEP DIHYDROCHLORIDE; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR ANTAGONIST; MUSCARINIC RECEPTOR; PROMETHAZINE; PROPAFENONE; SEROTONIN RECEPTOR; TRIMIPRAMINE; UNCLASSIFIED DRUG; ZIDOVUDINE; BAFILOMYCIN A1; BENZATROPINE; HEPARIN; MACROLIDE; MOLECULAR LIBRARY;

ANTIVIRAL ACTIVITY; ARTICLE; CELL MEMBRANE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG SCREENING; EBOLAVIRUS; HUMAN; HUMAN CELL; MARBURGVIRUS; MICROSCOPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TARGETING; VIRUS ATTACHMENT; VIRUS ENTRY; VIRUS REPLICATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; CHLOROCEBUS AETHIOPS; DRUG EFFECTS; HEK293 CELL LINE; HEMORRHAGIC FEVER, EBOLA; HIGH THROUGHPUT SCREENING; MARBURG VIRUS DISEASE; MOLECULAR LIBRARY; PATHOGENICITY; PHYSIOLOGY; VERO CELL LINE;

ANIMALS; ANTIVIRAL AGENTS; BENZTROPINE; CELL LINE; CERCOPITHECUS AETHIOPS; CYPROHEPTADINE; EBOLAVIRUS; HEK293 CELLS; HEMORRHAGIC FEVER, EBOLA; HEPARIN; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MACROLIDES; MARBURG VIRUS DISEASE; MARBURGVIRUS; RECEPTORS, G-PROTEIN-COUPLED; SMALL MOLECULE LIBRARIES; VERO CELLS; VIRUS INTERNALIZATION; ZIDOVUDINE;

EID: 84940997614     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01337-15     Document Type: Article

References (26)

1. Feldmann F, Sanchez A, Geisbert JB. 2013. Filoviridae: Marburg and Ebola viruses, p 923-956. In Knipe DM, Howley PM (ed), Fields virology, 6th ed, vol II. Wolters Kluwer Lippincott Willliams & Wilkins, Philadelphia, PA.
2. Leroy EM, Kumulungui B, Pourrut X, Rouquet P, Hassanin A, Yaba P, Delicat A, Paweska JT, Gonzalez JP, Swanepoel R. 2005. Fruit bats as reservoirs of Ebola virus. Nature 438:575-576. http://dx.doi.org/10.1038/438575a.
3. Qiu X, Wong G, Audet J, Bello A, Fernando L, Alimonti JB, Fausther-Bovendo H, Wei H, Aviles J, Hiatt E, Johnson A, Morton J, Swope K, Bohorov O, Bohorova N, Goodman C, Kim D, Pauly MH, Velasco J, Pettitt J, Olinger GG, Whaley K, Xu B, Strong JE, Zeitlin L, Kobinger GP. 2014. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 514:47-53. http://dx.doi.org/10.1038/nature13777.
4. Sullivan NJ, Geisbert TW, Geisbert JB, Xu L, Yang ZY, Roederer M, Koup RA, Jahrling PB, Nabel GJ. 2003. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 424:681-684. http://dx.doi.org/10.1038/nature01876.
5. Warren TK, Wells J, Panchal RG, Stuthman KS, Garza NL, Van Tongeren SA, Dong L, Retterer CJ, Eaton BP, Pegoraro G, Honnold S, Bantia S, Kotian P, Chen X, Taubenheim BR, Welch LS, Minning DM, Babu YS, Sheridan WP, Bavari S. 2014. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature 508:402-405. http://dx.doi.org/10.1038/nature13027.
6. O'Hearn A, Wang M, Cheng H, Lear-Rooney CM, Koning K, Rumschlag-Booms E, Varhegyi E, Olinger G, Rong L. 2015. Role of EXT1 and glycosaminoglycans in the early stage of filovirus entry. J Virol 89:5441-5449. http://dx.doi.org/10.1128/JVI.03689-14.
7. Salvador B, Sexton NR, Carrion R, Jr, Nunneley J, Patterson JL, Steffen I, Lu K, Muench MO, Lembo D, Simmons G. 2013. Filoviruses utilize glycosaminoglycans for their attachment to target cells. J Virol 87:3295-3304. http://dx.doi.org/10.1128/JVI.01621-12.
8. Team RDC. 2011. R: a language and environment for statistical computing. R Foundation for Statistical computing, Vienna, Austria.
9. Wang J, Cheng H, Ratia K, Varhegyi E, Hendrickson WG, Li J, Rong L. 2014. Acomparative high-throughput screening protocol to identify entry inhibitors of enveloped viruses. J Biomol Screen 19:100-107. http://dx.doi.org/10.1177/1087057113494405.
10. Manicassamy B, Wang J, Jiang H, Rong L. 2005. Comprehensive analysis of Ebola virus GP1 in viral entry. J Virol 79:4793-4805. http://dx.doi.org/10.1128/JVI.79.8.4793-4805.2005.
11. Kroeze WK, Sheffler DJ, Roth BL. 2003. G-protein-coupled receptors at a glance. J Cell Sci 116:4867-4869. http://dx.doi.org/10.1242/jcs.00902.
12. Rivals I, Personnaz L, Taing L, Potier MC. 2007. Enrichment or depletion of a GO category within a class of genes: which test? Bioinformatics 23:401-407. http://dx.doi.org/10.1093/bioinformatics/btl633.
13. Gelenberg AJ, Van Putten T, Lavori PW, Wojcik JD, Falk WE, Marder S, Galvin-Nadeau M, Spring B, Mohs RC, Brotman AW. 1989. Anticholinergic effects on memory: benztropine versus amantadine. J Clin Psychopharmacol 9:180-185.
14. Basu A, Li B, Mills DM, Panchal RG, Cardinale SC, Butler MM, Peet NP, Majgier-Baranowska H, Williams JD, Patel I, Moir DT, Bavari S, Ray R, Farzan MR, Rong L, Bowlin TL. 2011. Identification of a smallmolecule entry inhibitor for filoviruses. J Virol 85:3106-3119. http://dx.doi.org/10.1128/JVI.01456-10.
15. Bowman EJ, Siebers A, Altendorf K. 1988. Bafilomycins: a class of inhibitors of membrane ATPases from microorganisms, animal cells, and plant cells. Proc Natl Acad Sci U S A 85:7972-7976. http://dx.doi.org/10.1073/pnas.85.21.7972.
16. Mitsuya H, Yarchoan R, Broder S. 1990. Molecular targets for AIDS therapy. Science 249:1533-1544. http://dx.doi.org/10.1126/science.1699273.
17. Rajagopal S, Rajagopal K, Lefkowitz RJ. 2010. Teaching old receptors new tricks: biasing seven-transmembrane receptors. Nat Rev Drug Discov 9:373-386. http://dx.doi.org/10.1038/nrd3024.
18. Sodhi A, Montaner S, Gutkind JS. 2004. Viral hijacking of G-proteincoupled-receptor signalling networks. Nat Rev Mol Cell Biol 5:998-1012. http://dx.doi.org/10.1038/nrm1529.
19. Saeed MF, Kolokoltsov AA, Freiberg AN, Holbrook MR, Davey RA. 2008. Phosphoinositide-3 kinase-Akt pathway controls cellular entry of Ebola virus. PLoS Pathog 4:e1000141. http://dx.doi.org/10.1371/journal.ppat.1000141.
20. Shimojima M, Takada A, Ebihara H, Neumann G, Fujioka K, Irimura T, Jones S, Feldmann H, Kawaoka Y. 2006. Tyro3 family-mediated cell entry of Ebola and Marburg viruses. J Virol 80:10109-10116. http://dx.doi.org/10.1128/JVI.01157-06.
21. Schornberg KL, Shoemaker CJ, Dube D, Abshire MY, Delos SE, Bouton AH, White JM. 2009. Alpha5beta1-integrin controls ebolavirus entry by regulating endosomal cathepsins. Proc Natl Acad Sci U S A 106:8003-8008. http://dx.doi.org/10.1073/pnas.0807578106.
22. Carette JE, Raaben M, Wong AC, Herbert AS, Obernosterer G, Mulherkar N, Kuehne AI, Kranzusch PJ, Griffin AM, Ruthel G, Cin PD, Dye JM, Whelan SP, Chandran K, Brummelkamp TR. 2011. Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature 477: 340-343. http://dx.doi.org/10.1038/nature10348.
23. Cote M, Misasi J, Ren T, Bruchez A, Lee K, Filone CM, Hensley L, Li Q, Ory D, Chandran K, Cunningham J. 2011. Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection. Nature 477: 344-348. http://dx.doi.org/10.1038/nature10380.
24. Chandran K, Sullivan NJ, Felbor U, Whelan SP, Cunningham JM. 2005. Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection. Science 308:1643-1645. http://dx.doi.org/10.1126/science.1110656.
25. Sakurai Y, Kolokoltsov AA, Chen CC, Tidwell MW, Bauta WE, Klugbauer N, Grimm C, Wahl-Schott C, Biel M, Davey RA. 2015. Ebola virus. Two-pore channels control Ebola virus host cell entry and are drug targets for disease treatment. Science 347:995-998. http://dx.doi.org/10.1126/science.1258758.
26. Kouznetsova J, Sun W, Martinez-Romero C, Tawa G, Shinn P, Chen CZ, Schimmer A, Sanderson P, McKew JC, Zheng W, Garcia-Sastre A. 2014. Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs. Emerg Microbes Infect 3:e84. http://dx.doi.org/10.1038/emi.2014.88.